Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says
Executive Summary
Quarantines, travel restrictions and supply chain interruptions are likely to cause 'unavoidable protocol deviations' in ongoing clinical trials, FDA says in new guidance that encourages sponsors to consider whether alternative means for conducting safety assessments and collecting efficacy data should be implemented in light of the disruptions caused by the coronavirus.
You may also be interested in...
Decentralized Clinical Trials Could Affect Validity Of Non-Inferiority Finding, US FDA Says
Draft guidance notes that data obtained from a decentralized clinical trial may be less precise than that from a site-based trial, creating challenges in calculating a non-inferiority margin. FDA specifies what should be included in DCT data management, trial monitoring and safety monitoring plans.
Pharma Companies Are Suspending Trials In Russia – But For Practical More Than Ethical Reasons
While pharma is keen to condemn Russia’s aggression, suspension of trials is driven by logistical considerations; US FDA said it stands ready to assist sponsors of disrupted trials in Russia and Ukraine to help ensure the safety of trial participants and integrity of the studies.
Stock Watch: Summit’s Stock Plummets
What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.